Loading
Giving all three chemotherapy drugs at once rather than two added four months of life, and worked whatever the RAS or BRAF status. It is the most intensive first-line option for patients fit enough to take it.
TRIBE was an open-label phase 3 randomised study in patients with unresectable metastatic colorectal cancer recruited from 34 Italian oncology units, aged 18 to 70 with ECOG performance status of 2 or less, or 71 to 75 with performance status 0. Patients were randomised 1:1 to FOLFIRI plus bevacizumab or FOLFOXIRI plus bevacizumab; tissue for RAS and BRAF status was collected centrally. This updated analysis reports overall survival, a secondary endpoint, and treatment efficacy in the molecular subgroups.
Between July 2008 and May 2011, 508 patients were randomised, and the trial closed on 30 November 2014.
The triplet is the option for fit patients who need a response, particularly in BRAF-mutant and right-sided disease where the EGFR antibody route is closed; it also quantified how much worse BRAF-mutant disease was before BEACON and BREAKWATER.
Shares FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3), FOLFIRI (5-FU, leucovorin, irinotecan), VEGF / VEGFR, Anti-angiogenic therapy and the tag colorectal-evidence.
Shares Irinotecan (and liposomal irinotecan), FOLFIRINOX / mFOLFIRINOX, Oxaliplatin, The Lancet Oncology and the tag colorectal-evidence.
Shares Irinotecan (and liposomal irinotecan), FOLFIRI (5-FU, leucovorin, irinotecan), Fluorouracil (5-FU), KRAS and the tag colorectal-evidence.
Shares Oxaliplatin, The Lancet Oncology, Fluorouracil (5-FU), Colorectal cancer and the tag colorectal-evidence.
Shares Oxaliplatin, Fluorouracil (5-FU), Toxicity and quality of life are undervalued, Cytotoxic chemotherapy and the tag colorectal-evidence.
Shares VEGF / VEGFR, Anti-angiogenic therapy, Bevacizumab, Cytotoxic chemotherapy and the tag colorectal-evidence.
Shares VEGF / VEGFR, Toxicity and quality of life are undervalued, Anti-angiogenic therapy, Colorectal cancer and the tag colorectal-evidence.
Shares FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3), VEGF / VEGFR, Bevacizumab, KRAS and the tag colorectal-evidence.